Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of
Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials
Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies.
The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd.
Canada’s Ongoing Struggle For Access To Natural Psilocybin As A Therapeutic Nabs Business Support
Ontario-based Red Light Holland Corp. (OTCQB: TRUFF) has committed to becoming an aligned supporter and advocate with the non-profit TheraPsil.
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications with the United S
Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial
Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy.
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage
Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment
Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022.
The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15 million as of Feb. 14, 2023.
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder.
How Do Psilocybin And MDMA Work Together? This Proposed Experiential Study Is Set To Find Out
Licensed psychedelic drugs producer Optimi Health Corp. (OTCQX: OPTHF) submitted a Health Canada clinical trial application (CTA) for a Phase 1 study that will assess the safety of combining its natural psilocybin standardized extract with its proprietary MDMA drug candidate in healthy therapists.
A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral,